Jesse Treu, Ph.D.

Board Director

Jesse Treu, Ph.D.

Dr. Treu has been a Partner of Domain since its inception in 1985.  He has been a director of more than 30 early-stage health care companies, 18 of which have so far become successful public companies.  At present, his board memberships include Afferent Pharmaceuticals, CoLucid Pharmaceuticals, Regado Biosciences, Tandem Diabetes Care and Veracyte.  He has served as a Founder, President and Chairman of numerous venture stage companies.  Prior to the formation of Domain, Dr. Treu was vice president of the predecessor organization to The Wilkerson Group, and its venture capital arm, CW Ventures.  While at CW Ventures, he served as President and CEO of Microsonics, a pioneer in computer image processing for cardiology.  Prior to that, Dr. Treu held executive positions at Technicon Instruments Corporation (now Siemens Medical Solutions Diagnostics), and at GE.

Education:
B.S. - Rensselaer Polytechnic Institute, 1968
M.A. & Ph.D. - Princeton University, 1971, 1973

www.domainvc.com

Back to List

About Colucid

CoLucid was founded in 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatments for CNS disorders. The company's investors include Pappas Ventures, Domain Associates, Care Capital, Pearl Street Venture Funds and Triathlon Medical Ventures.

Learn More About CoLucid

Lasmiditan

image of lasmiditan structure

Lasmiditan is a member of a novel chemical class called "ditans." Lasmiditan penetrates the central nervous system (CNS) and selectively targets 5-HT1F receptors expressed in the trigeminal nerve pathway.

Learn More About Lasmiditan